Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ribupatide injection in adults with obesity and knee osteoarthritis
CTR20262669Phase 3Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of ribupatide in obesity, osteoarthritis (OA), sponsored by Fujian Shengdi Pharmaceuticals. Started Jul 2026; status: active.
02
Drugs
ribupatide
03
Conditions
obesityosteoarthritis (OA)
Beyond the preview
Go deeper on CTR20262669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262669.